Cure Parkinson’s and Alzheimer’s Research UK announce a partnership
Cure Parkinson’s and Alzheimer’s Research UK are working on an initiative that could pave the way for innovative neurodegenerative treatments. There is a growing recognition that tackling neurodegenerative diseases could benefit from a collaborative, cross-disease approach. We are recognising the overlap in underlying biological...
Learn more
Improving diversity in Parkinson’s research – The East London Parkinson’s Disease Project
The East London Parkinson’s Disease Project (ELPD) is a study led by Professor Alastair Noyce at Queen Mary University London. This Cure Parkinson’s supported initiative seeks to better understand the experiences of people with Parkinson’s from diverse ethnic backgrounds. Recently, the ELPD team published a…
Meet the Researcher: Dr Poonam Thakur on prioritising preclinical research
In this new series from Cure Parkinson’s, we’ll be hearing directly from the scientists putting our funded research projects into action. From learning about their career journeys, to getting an inside look at their studies, we’ll discover how their work aims to support people living…
SLEIPNIR, the new multi-arm clinical trial platform for Parkinson’s treatments
Cure Parkinson’s is excited to announce £1 million in funding for SLEIPNIR – an upcoming multi-arm clinical trial platform in Norway. One of the ongoing challenges for Parkinson’s research is determining whether treatments are reaching the brain and if they are having their intended effect…
New findings from the TransEuro cell replacement trial are now published
Parkinson’s is characterised by the progressive loss of dopamine nerve cells (neurons) in an area of the brain associated with movement. Therefore, researchers have been investigating whether cell transplantations have potential to replace the neurons lost, to slow or reverse progression of the condition. What…
Cure Parkinson’s welcomes a new research committee chair
Every research project that Cure Parkinson’s funds must be recommended by our research committee – an independent board of leading Parkinson’s researchers, clinicians, people with Parkinson’s, patient advocates and experts in intellectual property and regulatory affairs, who meet four times a year to evaluate new…